Artículos recomendados
Artículos recomendados
Nature Reviews / NEUROSCIENCE
Volumen 9, Número 10, Páginas 768-778; Octubre, 2008Thirty years of Alzheimer’s disease genetics: the implications of systematic meta-analyses.
Lars Bertram and Rudolph E. TanziGenetics and Aging Research Unit, MassGeneral Institute for Neurodegenerative Diseases (MIND), Department of Neurology, Massachusetts General Hospital, 114 16th Street, Charlestown, Massachusetts 02129, USA.
Neurobiology of Aging
Volume 28, Issue 10, Pages 1465-1636; October, 2007Is aging part of Alzheimer’s disease, or is Alzheimer’s disease part of aging?
Russell H. SwerdlowDepartment of Neurology, University of Virginia Health System, McKim Hall, 1 Hospital Drive, P.O. Box 800394, Charlottesville, VA 22908, United States.
TRENDS in Molecular Medicine
Volumen 11, Número 4, Páginas 145-197; Abril, 2005Tau phosphorylation in Alzheimer’s disease: pathogen or protector?
Hyoung-gon Lee (1), George Perry (1), Paula I. Moreira (1), (2), Matthew R. Garrett (1), Quan Liu (1), Xiongwei Zhu (1), Atsushi Takeda (3), Akihiko Nunomura (4) and Mark A. Smith (1)1. Institute of Pathology, Case Western Reserve University, Cleveland, OH 44106 USA. 2. Center for Neuroscience and Cell Biology of Coimbra, University of Coimbra, 3004-517 Coimbra, Portugal. 3. Department of Neurology, Tohoku University School of Medicine, Sendai, Miyagi 980-8574, Japan. 4. Department of Psychiatry and Neurology, Asahikawa Medical College, Asahikawa 078-8510, Japan.
Physiological Reviews
Volume 84, Issue 2, Pages 361-384; April, 2004Role of Tau Protein in Both Physiological and Pathological Conditions
Jesús Avila, José J. Lucas, Mar Pérez, and Félix Hernández.Centro de Biología Molecular “Severo Ochoa” (CSIC-UAM), Facultad de Ciencias, Campus de Cantoblanco, Madrid, Spain
Neurobiology of Aging
Volumen 25, Número 3, Páginas 273-416; Marzo, 2004Neurochemical diagnosis of Alzheimer’s dementia by CSF A42, A42/A40 ratio and total tau
Piotr Lewczuk a, Hermann Esselmann b , Markus Otto b , Juan Manuel Maler a , Andreas Wolfram Henkel a , Maria Kerstin Henkel a , Oliver Eikenberg c , Christof Antz c , Wolf-Rainer Krause d , Udo Reulbach e , Johannes Kornhuber, Jens Wiltfang a.a Molecular Neurobiology Lab, Department of Psychiatry and Psychotherapy, University of Erlangen-Nuremberg, Schwabachanlage 6, 91054 Erlangen, Germany. b Department of Psychiatry, University of Goettingen, von-Siebold-Str. 5, 37075 Goettingen, Germany. c ABETA GmbH, Im Neuenheimer Feld 584, 69120 Heidelberg, Germany. d Department of Psychiatry and Psychotherapy, Thiestr. 7-10, 38889 Blankenburg, Germany. e Department of Medical Informatics,…
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY
Volumen 43, Páginas 545-584; Abril, 2003ALZHEIMER’S DISEASE: Molecular Understanding Predicts Amyloid-Based Therapeutics
Dennis J. Selkoe¹ and Dale Schenk²¹Harvard Medical School and Brigham and Women’s Hospital, Boston, Massachusetts 02115 ²Elan Pharmaceuticals, South San Francisco, California 94080
La Enfermedad de Alzheimer
Manuel SarasaDirector Científico de Araclon Biotech, Zaragoza, España.
PHYSIOLOGICAL REVIEWS
Volumen 81, Número 2, Páginas 741-766; Abril, 2001Alzheimer’s Disease: Genes, Proteins, and Therapy
Dennis J. SelkoeDepartment of Neurology and Program in Neuroscience, Harvard Medical School, and Center for Neurologic Diseases, Brigham and Women’s Hospital, Boston, Massachusetts.